Cravit Indications/Uses

Treatment of adults (≥16 years) with mild, moderate and severe infections caused by susceptible strains of the designated microorganisms in the following conditions: Acute sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis.
Acute exacerbation of chronic bronchitis due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae or Moraxella catarrhalis.
Community-acquired pneumonia due to Staphylococcus aureus, Streptococcus pneumoniae (including penicillin-resistant strains), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae, Legionella pneumophila or Mycoplasma pneumoniae.
Nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended.
Uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma and wound infections due to Staphylococcus aureus and Streptococcus pyogenes.
Complicated skin and skin structure infections (mild to moderate) due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes or Proteus mirabilis.
Urinary tract infection (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa or Staphylococcus saprophyticus.
Chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis and Staphylococcus epidermidis.
Pyelonephritis (mild to moderate) caused by Escherichia coli.
Empirical treatment for community-acquired pneumonia most likely caused by organisms susceptible to levofloxacin.
Third-line therapy for Helicobacter pylori infection.
Levofloxacin-Based Triple Therapy: Levofloxacin, in combination with other antimicrobial agents and proton-pump inhibitor as triple therapy is indicated for the treatment of patients with gastric ulcer caused by H. pylori infection and duodenal ulcer disease.